{
  "symbol": "ABT",
  "year": 2024,
  "competition_summary": [
    {
      "competitor": "Abbott Laboratories",
      "mentions": 2,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Contents Diagnostic Products",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Alinity",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Cell-Dyn \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Alinity \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "HPV",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "RSV",
      "mentions": 2,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Viral Load Test",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Afinion \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Cholestech",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "GLP",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "RALS \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "AlinIQ \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Nutritional Products",
      "mentions": 2,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Similac Total Comfort \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "NutriVigor",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Abound",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Freego",
      "mentions": 2,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Vital \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Abbott\u2019s",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Medical Devices",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Assurity MRI \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Fortify",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "MultiPoint",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "TactiCath",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "FlexAbility \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "EnSite \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Swartz",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Advisor",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "the Multi-Link Vision \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "StarClose",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "ProStyle \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Supera \u00ae Peripheral Stent System",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "OPTIS",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Ultreon",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "OpStar \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "PressureWire \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Epic \u00ae",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "PFO",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Proclaim \u00ae Plus",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "the Infinity \u00ae Deep Brain Stimulation System",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "RESPECT",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "COVID-19",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "the \"Financial Review",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Management\u2019s Discussion and Analysis of Financial Condition",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Abbott",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "the Narrative Description of Business",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Seasonal Aspects, Customers",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    },
    {
      "competitor": "Renegotiation",
      "mentions": 1,
      "context": "Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term \u201cAbbott\u201d refers to Abbott "
    }
  ]
}